Drug Trial Radar · NCT05608044
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
234
Actual
Start
Nov 30, 2022
Primary completion
Sep 2027
Study completion Sep 2029
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
Conditions
- Metastatic Colorectal Cancer
Interventions
BotensilimabDrug
An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
BalstilimabDrug
An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
Standard of CareDrug
Regorafenib or trifluridine and tipiracil.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: First dose through up to 2 years
Locations
65 sites in 8 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
City of Hope National Medical Center
Duarte, California
Keck School of Medicine of the University of Southern California
Los Angeles, California
Rocky Mountain Cancer Center - Aurora
Aurora, Colorado
University of Colorado
Denver, Colorado
Medical Oncology Hematology Consultants
Newark, Delaware
Florida Cancer Specialists and Research Institute - Lake Mary
Lake Mary, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey
Weill Cornell Medicine
New York, New York
Mount Sinai Hospital - New York
New York, New York
Memorial Sloan Kettering
New York, New York
Cleveland Clinic
Cleveland, Ohio
Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute
Portland, Oregon
Oregon Health & Science University (OHSU)
Portland, Oregon
Lifespan Clinical Research Center/Cancer Institute (Providence Rhode Island)
East Providence, Rhode Island
Tennessee Oncology Nashville (Sarah Cannon)
Nashville, Tennessee
Vanderbilt University School of Medicine
Nashville, Tennessee
Texas Oncology - Austin Midtown
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
MDACC
Houston, Texas
Virginia Cancer Specialists/NEXT Virginia
Fairfax, Virginia
Swedish Cancer Institute
Seattle, Washington
Northwest Cancer Center Specialists - Vancouver Cancer Center - Compass Oncology Vancouver
Vancouver, Washington
Antwerp University Hospital (UZA)
Edegem, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Hospital Sirio Libanes Brasilia
Brasília, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia
Ijuí, Brazil
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Porto Alegre, Brazil
Instituto Sul Mineiro de Oncologia - ONCOMINAS
Pouso Alegre, Brazil
Instituto Americas
Rio de Janeiro, Brazil
Hospital A.C. Camargo Cancer Center
São Paulo, Brazil
Centro Paulista de Oncologia
São Paulo, Brazil
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
Jaú, São Paulo, Brazil
Service d'Oncologie Medicale - CHRU Besancon
Besançon, France
Institut Paoli-Calmettes
Marseille, France
Hôpital Saint Antoine/AP-HP Hopital Saint Antoine (Pierre and Marie Curie University)
Paris, France
CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC)
Poitiers, France
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.